Prognostic value of [¹⁸F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies.

ABSTRACT:

Purpose

Current clinical and imaging tools remain suboptimal for predicting treatment response and prognosis in CNS lymphomas. We investigated the prognostic value of baseline [¹⁸F]FDG PET in patients with CNS lymphoma receiving ibrutinib-based treatments.

Methods

Fifty-three patients enrolled in a prospective clinical trial and underwent brain PET before receiving single-agent ibrutinib or ibrutinib in combination with methotrexate with or without rituximab. [¹⁸F]FDG uptake in these lesions was quantified by drawing PET volumes of interest around up to five [¹⁸F]FDG-avid lesions per patient (with uptake greater than surrounding brain). We measured standardized uptake values (SUV_max), metabolic tumor volumes, total lesion glycolysi

SUBMITTER: Krebs S 

PROVIDER: S-EPMC8484020 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature